Muscat (AFP) | 23/12/2025 - 11:28:11 | Houthis, Yemen government to exchange nearly 3,000 prisoners: officials
Washington (AFP) | 23/12/2025 - 11:18:52 | Thousands of new Epstein-linked documents released by US Justice Dept
Sydney (AFP) | 23/12/2025 - 11:08:52 | Australia PM to invite Israeli president to visit
Geneva (AFP) | 23/12/2025 - 09:48:15 | UN says Myanmar junta using 'brutal violence' to force people to vote
Washington (AFP) | 23/12/2025 - 05:26:36 | Latest US strike on alleged drug boat in eastern Pacific kills one: US military
Caracas (AFP) | 23/12/2025 - 01:30:58 | Maduro says Trump would be 'better off' focusing on US rather than Venezuela
Washington (AFP) | 23/12/2025 - 01:24:27 | US approves first GLP-1 pill for weight loss: Novo Nordisk
Palm Beach (AFP) | 23/12/2025 - 00:23:52 | Trump says would be 'smart' for Venezuela's Maduro to step down
Lagos (AFP) | 22/12/2025 - 23:55:52 | Gunmen kidnap 28 people on a Muslim religious trip in Nigeria: security report
Palm Beach (AFP) | 22/12/2025 - 23:45:21 | Trump announces new US warship class named after himself
The NPPA (National Press Photographers Association) Awards have honoured AFP photographer Luis Tato with three prizes in the Science, Science Story and Politics Story categories.
Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company developing precision medicines that modulate regulatory T cells (Tregs) to restore immune balance, today announced dosing of the first healthy volunteer in the Phase 1 clinical study of EGL-003, an IL‑2⍺-biased mutein designed to selectively activate Tregs while limiting effector T cell stimulation, as a potential treatment for atopic dermatitis. The open-label, multi-center Phase 1 trial begins with a single ascending dose p...
